AU2012251919B2 - Compositions for regulating iron homeostasis and methods of using same - Google Patents

Compositions for regulating iron homeostasis and methods of using same Download PDF

Info

Publication number
AU2012251919B2
AU2012251919B2 AU2012251919A AU2012251919A AU2012251919B2 AU 2012251919 B2 AU2012251919 B2 AU 2012251919B2 AU 2012251919 A AU2012251919 A AU 2012251919A AU 2012251919 A AU2012251919 A AU 2012251919A AU 2012251919 B2 AU2012251919 B2 AU 2012251919B2
Authority
AU
Australia
Prior art keywords
composition
fusion protein
subject
present disclosure
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012251919A
Other languages
English (en)
Other versions
AU2012251919A2 (en
AU2012251919A1 (en
Inventor
Jodie L. Babitt
Patrick GEARING
Herbert Y. Lin
Tracey MENHALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FERRUMAX PHARMACEUTICALS Inc
General Hospital Corp
Original Assignee
FERRUMAX PHARMACEUTICALS Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERRUMAX PHARMACEUTICALS Inc, General Hospital Corp filed Critical FERRUMAX PHARMACEUTICALS Inc
Publication of AU2012251919A1 publication Critical patent/AU2012251919A1/en
Publication of AU2012251919A2 publication Critical patent/AU2012251919A2/en
Application granted granted Critical
Publication of AU2012251919B2 publication Critical patent/AU2012251919B2/en
Priority to AU2017201782A priority Critical patent/AU2017201782B2/en
Priority to AU2019202913A priority patent/AU2019202913A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
AU2012251919A 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same Ceased AU2012251919B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017201782A AU2017201782B2 (en) 2011-01-19 2017-03-15 Compositions For Regulating Iron Homeostasis and Methods of Using Same
AU2019202913A AU2019202913A1 (en) 2011-01-19 2019-04-16 Compositions for regulating iron homeostasis and methods of using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434405P 2011-01-19 2011-01-19
US61/434,405 2011-01-19
PCT/US2012/021829 WO2012150973A1 (en) 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017201782A Division AU2017201782B2 (en) 2011-01-19 2017-03-15 Compositions For Regulating Iron Homeostasis and Methods of Using Same

Publications (3)

Publication Number Publication Date
AU2012251919A1 AU2012251919A1 (en) 2013-08-15
AU2012251919A2 AU2012251919A2 (en) 2014-06-12
AU2012251919B2 true AU2012251919B2 (en) 2016-12-15

Family

ID=47107987

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012251919A Ceased AU2012251919B2 (en) 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same
AU2017201782A Ceased AU2017201782B2 (en) 2011-01-19 2017-03-15 Compositions For Regulating Iron Homeostasis and Methods of Using Same
AU2019202913A Abandoned AU2019202913A1 (en) 2011-01-19 2019-04-16 Compositions for regulating iron homeostasis and methods of using same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017201782A Ceased AU2017201782B2 (en) 2011-01-19 2017-03-15 Compositions For Regulating Iron Homeostasis and Methods of Using Same
AU2019202913A Abandoned AU2019202913A1 (en) 2011-01-19 2019-04-16 Compositions for regulating iron homeostasis and methods of using same

Country Status (8)

Country Link
US (2) US9708379B2 (https=)
EP (1) EP2665752B1 (https=)
JP (2) JP2014506452A (https=)
KR (1) KR102035357B1 (https=)
CN (2) CN103649126B (https=)
AU (3) AU2012251919B2 (https=)
CA (1) CA2825163C (https=)
WO (1) WO2012150973A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070242A1 (en) * 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
EP2791175A2 (en) * 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CN104144947B (zh) 2011-12-14 2017-10-27 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
EP3471759A1 (en) 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2019136043A1 (en) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CN114761013A (zh) * 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
US20230061804A1 (en) * 2020-01-23 2023-03-02 The Rockefeller University Phase separation sensors and uses thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022271716A2 (en) * 2021-06-21 2022-12-29 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
WO2009030500A1 (en) * 2007-09-06 2009-03-12 Abbott Gmbh & Co. Kg Bone morphogenetic protein (bmp)-binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and use of same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2004092405A2 (en) * 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
CA2549477A1 (en) * 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
EP1862555A1 (en) * 2006-05-29 2007-12-05 Klinikum der Universität Regensburg Means and methods for diagnosing cancer or a corresponding predisposition
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
WO2009074637A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
US20120264686A9 (en) * 2008-05-29 2012-10-18 Hanall Biopharma Co. Ltd Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
JP6018753B2 (ja) * 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
WO2009030500A1 (en) * 2007-09-06 2009-03-12 Abbott Gmbh & Co. Kg Bone morphogenetic protein (bmp)-binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and use of same

Also Published As

Publication number Publication date
KR102035357B1 (ko) 2019-10-23
AU2012251919A2 (en) 2014-06-12
US20140199302A1 (en) 2014-07-17
CA2825163A1 (en) 2012-11-08
AU2012251919A1 (en) 2013-08-15
KR20140030134A (ko) 2014-03-11
EP2665752B1 (en) 2018-10-10
AU2017201782A1 (en) 2017-03-30
CN107022032A (zh) 2017-08-08
US20180044389A1 (en) 2018-02-15
JP2014506452A (ja) 2014-03-17
AU2019202913A1 (en) 2019-05-16
AU2017201782B2 (en) 2019-01-17
CA2825163C (en) 2019-12-03
JP2017025070A (ja) 2017-02-02
US9708379B2 (en) 2017-07-18
JP6466376B2 (ja) 2019-02-06
EP2665752A1 (en) 2013-11-27
CN103649126B (zh) 2016-11-09
EP2665752A4 (en) 2014-09-17
WO2012150973A9 (en) 2013-01-17
WO2012150973A1 (en) 2012-11-08
US10273273B2 (en) 2019-04-30
CN103649126A (zh) 2014-03-19

Similar Documents

Publication Publication Date Title
AU2012251919B2 (en) Compositions for regulating iron homeostasis and methods of using same
US10869909B2 (en) Compositions and methods of use for treating metabolic disorders
EP3816625B1 (en) Compositions and methods for growth factor modulation
US10610568B2 (en) Compositions and methods of use for treating metabolic disorders
US10323075B2 (en) Compositions and methods of use for treating metabolic disorders
JP2019123719A (ja) インターロイキン−１０を疾病及び疾患の治療に用いる方法
JP2016526014A (ja) インターロイキン−１０組成物及びその使用
CN105705160B (zh) Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
KR20170084033A (ko) 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
US9388213B2 (en) Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
US10456451B2 (en) Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
Shi et al. Site-specific PEGylation of human growth hormone by mutated sortase A
HK1241391A1 (en) Compositions for regulating iron homeostasis and methods of using same
HK40048816B (en) Compositions and methods for growth factor modulation
WO2014014816A2 (en) Methods of treating glucose metabolism disorders
WO2013151627A1 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 MAY 2014

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired